Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

The role of the microbiome in NAFLD and NASH.

Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E.

EMBO Mol Med. 2018 Dec 27. pii: e9302. doi: 10.15252/emmm.201809302. [Epub ahead of print] Review.

2.

Circulating Endocannabinoids Are Reduced Following Bariatric Surgery and Associated with Improved Metabolic Homeostasis in Humans.

Azar S, Sherf-Dagan S, Nemirovski A, Webb M, Raziel A, Keidar A, Goitein D, Sakran N, Shibolet O, Tam J, Zelber-Sagi S.

Obes Surg. 2019 Jan;29(1):268-276. doi: 10.1007/s11695-018-3517-0.

PMID:
30244333
3.

Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT.

Suez J, Zmora N, Zilberman-Schapira G, Mor U, Dori-Bachash M, Bashiardes S, Zur M, Regev-Lehavi D, Ben-Zeev Brik R, Federici S, Horn M, Cohen Y, Moor AE, Zeevi D, Korem T, Kotler E, Harmelin A, Itzkovitz S, Maharshak N, Shibolet O, Pevsner-Fischer M, Shapiro H, Sharon I, Halpern Z, Segal E, Elinav E.

Cell. 2018 Sep 6;174(6):1406-1423.e16. doi: 10.1016/j.cell.2018.08.047.

PMID:
30193113
4.

Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features.

Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashiardes S, Kotler E, Zur M, Regev-Lehavi D, Brik RB, Federici S, Cohen Y, Linevsky R, Rothschild D, Moor AE, Ben-Moshe S, Harmelin A, Itzkovitz S, Maharshak N, Shibolet O, Shapiro H, Pevsner-Fischer M, Sharon I, Halpern Z, Segal E, Elinav E.

Cell. 2018 Sep 6;174(6):1388-1405.e21. doi: 10.1016/j.cell.2018.08.041.

PMID:
30193112
5.

The Critical Role of Chemokine (C-C Motif) Receptor 2-Positive Monocytes in Autoimmune Cholangitis.

Reuveni D, Gore Y, Leung PSC, Lichter Y, Moshkovits I, Kaminitz A, Brazowski E, Lefebvre E, Vig P, Varol C, Halpern Z, Shibolet O, Gershwin ME, Zigmond E.

Front Immunol. 2018 Aug 15;9:1852. doi: 10.3389/fimmu.2018.01852. eCollection 2018.

6.

POLD1 and POLE Gene Mutations in Jewish Cohorts of Early-Onset Colorectal Cancer and of Multiple Colorectal Adenomas.

Rosner G, Gluck N, Carmi S, Bercovich D, Fliss-Issakov N, Ben-Yehoyada M, Aharon-Caspi S, Kellerman E, Strul H, Shibolet O, Kariv R.

Dis Colon Rectum. 2018 Sep;61(9):1073-1079. doi: 10.1097/DCR.0000000000001150.

PMID:
30086056
7.

68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study.

Kesler M, Levine C, Hershkovitz D, Mishani E, Menachem Y, Lerman H, Zohar Y, Shibolet O, Even-Sapir E.

J Nucl Med. 2018 Jul 12. pii: jnumed.118.214833. doi: 10.2967/jnumed.118.214833. [Epub ahead of print]

PMID:
30002112
8.

Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization.

Ventura Y, Carr BI, Kori I, Guerra V, Shibolet O.

World J Gastroenterol. 2018 Apr 21;24(15):1641-1649. doi: 10.3748/wjg.v24.i15.1641.

9.

Crohn's Disease Behavior and Location is Altered when Associated with Primary Sclerosing Cholangitis.

Iny O, Yanai H, Matalon S, Santo E, Shibolet O, Dotan I, Maharshak N.

Isr Med Assoc J. 2018 Jan;20(1):25-29.

10.

Progression and new onset of nonalcoholic fatty liver disease in living kidney donors compared to healthy controls.

Katchman H, Zelber-Sagi S, Baruch R, Berman G, Schwartz IF, Schwartz D, Nakache R, Goykhman Y, Katz P, Shibolet O, Shashar M, Grupper A.

Clin Transplant. 2018 May;32(5):e13240. doi: 10.1111/ctr.13240. Epub 2018 Apr 10.

PMID:
29575023
11.

High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance.

Zelber-Sagi S, Ivancovsky-Wajcman D, Fliss Isakov N, Webb M, Orenstein D, Shibolet O, Kariv R.

J Hepatol. 2018 Jun;68(6):1239-1246. doi: 10.1016/j.jhep.2018.01.015. Epub 2018 Mar 20.

PMID:
29571924
12.

Obesity-related acetylcholinesterase elevation is reversed following laparoscopic sleeve gastrectomy.

Shenhar-Tsarfaty S, Sherf-Dagan S, Berman G, Webb M, Raziel A, Keidar A, Goitein D, Sakran N, Zwang E, Shapira I, Zeltser D, Berliner S, Rogowski O, Shibolet O, Zelber-Sagi S.

Int J Obes (Lond). 2018 Feb 3. doi: 10.1038/s41366-018-0014-4. [Epub ahead of print]

PMID:
29491490
13.

Distinct Metabolic Profiles are Associated with Colorectal Adenomas and Serrated Polyps.

Fliss-Isakov N, Zelber-Sagi S, Webb M, Halpern Z, Shibolet O, Kariv R.

Obesity (Silver Spring). 2017 Nov;25 Suppl 2:S72-S80. doi: 10.1002/oby.22001.

14.

Hepatic Amiodarone Lipotoxicity Is Ameliorated by Genetic and Pharmacological Inhibition of Endoplasmatic Reticulum Stress.

Erez N, Hubel E, Avraham R, Cohen R, Fishman S, Bantel H, Manns M, Tirosh B, Zvibel I, Shibolet O.

Toxicol Sci. 2017 Oct 1;159(2):402-412. doi: 10.1093/toxsci/kfx143.

PMID:
28962527
15.

Probiotics administration following sleeve gastrectomy surgery: a randomized double-blind trial.

Sherf-Dagan S, Zelber-Sagi S, Zilberman-Schapira G, Webb M, Buch A, Keidar A, Raziel A, Sakran N, Goitein D, Goldenberg N, Mahdi JA, Pevsner-Fischer M, Zmora N, Dori-Bachash M, Segal E, Elinav E, Shibolet O.

Int J Obes (Lond). 2018 Feb;42(2):147-155. doi: 10.1038/ijo.2017.210. Epub 2017 Aug 30.

PMID:
28852205
16.

Erratum to: Nutritional Status Prior to Laparoscopic Sleeve Gastrectomy Surgery.

Sherf Dagan S, Zelber-Sagi S, Webb M, Keidar A, Raziel A, Sakran N, Goitein D, Shibolet O.

Obes Surg. 2017 Sep;27(9):2511. doi: 10.1007/s11695-017-2815-2. No abstract available.

PMID:
28681259
17.

Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.

Horsmans Y, Zhou J, Liudmila M, Golor G, Shibolet O, Quinlan M, Emotte C, Boss H, Castro H, Sellami D, Preston RA.

Clin Pharmacokinet. 2018 Mar;57(3):345-354. doi: 10.1007/s40262-017-0560-2.

PMID:
28577129
18.

Role of illness perception and self-efficacy in lifestyle modification among non-alcoholic fatty liver disease patients.

Zelber-Sagi S, Bord S, Dror-Lavi G, Smith ML, Towne SD Jr, Buch A, Webb M, Yeshua H, Nimer A, Shibolet O.

World J Gastroenterol. 2017 Mar 14;23(10):1881-1890. doi: 10.3748/wjg.v23.i10.1881.

19.

Do Bariatric Patients Follow Dietary and Lifestyle Recommendations during the First Postoperative Year?

Sherf Dagan S, Keidar A, Raziel A, Sakran N, Goitein D, Shibolet O, Zelber-Sagi S.

Obes Surg. 2017 Sep;27(9):2258-2271. doi: 10.1007/s11695-017-2633-6.

PMID:
28303504
20.

Protective role of soluble receptor for advanced glycation end-products in patients with non-alcoholic fatty liver disease.

Zelber-Sagi S, Salomone F, Kolodkin-Gal I, Erez N, Buch A, Yeshua H, Webb M, Halpern Z, Shibolet O.

Dig Liver Dis. 2017 May;49(5):523-529. doi: 10.1016/j.dld.2017.01.148. Epub 2017 Jan 19.

PMID:
28179090
21.

Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients.

Zelber-Sagi S, Shoham D, Zvibel I, Abu-Abeid S, Shibolet O, Fishman S.

World J Hepatol. 2017 Jan 18;9(2):91-98. doi: 10.4254/wjh.v9.i2.91.

22.

HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.

Gozlan Y, Ben-Ari Z, Moscona R, Shirazi R, Rakovsky A, Kabat A, Veizman E, Berdichevski T, Weiss P, Cohen-Ezra O, Lurie Y, Gafanovich I, Braun M, Cohen-Naftaly M, Shlomai A, Shibolet O, Zigmond E, Zuckerman E, Carmiel-Haggai M, Nimer A, Hazzan R, Maor Y, Kitay-Cohen Y, Shemer-Avni Y, Kra-Oz Z, Schreiber L, Peleg O, Sierra S, Harrigan PR, Mendelson E, Mor O.

Antivir Ther. 2017;22(5):431-441. doi: 10.3851/IMP3123. Epub 2017 Jan 9.

PMID:
28067632
23.

Are transient and shear wave elastography useful tools in Gaucher disease?

Webb M, Zimran A, Dinur T, Shibolet O, Levit S, Steinberg DM, Salomon O.

Blood Cells Mol Dis. 2018 Feb;68:143-147. doi: 10.1016/j.bcmd.2016.12.010. Epub 2016 Dec 23.

PMID:
28063644
24.

Microbiota Diurnal Rhythmicity Programs Host Transcriptome Oscillations.

Thaiss CA, Levy M, Korem T, Dohnalová L, Shapiro H, Jaitin DA, David E, Winter DR, Gury-BenAri M, Tatirovsky E, Tuganbaev T, Federici S, Zmora N, Zeevi D, Dori-Bachash M, Pevsner-Fischer M, Kartvelishvily E, Brandis A, Harmelin A, Shibolet O, Halpern Z, Honda K, Amit I, Segal E, Elinav E.

Cell. 2016 Dec 1;167(6):1495-1510.e12. doi: 10.1016/j.cell.2016.11.003.

25.

Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease.

Zelber-Sagi S, Azar S, Nemirovski A, Webb M, Halpern Z, Shibolet O, Tam J.

Obesity (Silver Spring). 2017 Jan;25(1):94-101. doi: 10.1002/oby.21687. Epub 2016 Nov 15.

26.

Sortilin Deficiency Reduces Ductular Reaction, Hepatocyte Apoptosis, and Liver Fibrosis in Cholestatic-Induced Liver Injury.

Hubel E, Saroha A, Park WJ, Pewzner-Jung Y, Lavoie EG, Futerman AH, Bruck R, Fishman S, Dranoff JA, Shibolet O, Zvibel I.

Am J Pathol. 2017 Jan;187(1):122-133. doi: 10.1016/j.ajpath.2016.09.005. Epub 2016 Nov 11.

PMID:
27842214
27.

Liver Transplantation for a Patient with Hepatocellular Carcinoma with Vascular Invasion and Exceeding Milan Criteria-Happy End Despite it all.

Rozen R, Menachem Y, Carr BI, Shibolet O.

J Gastrointest Cancer. 2018 Jun;49(2):214-217. doi: 10.1007/s12029-016-9890-9. No abstract available.

PMID:
27834046
28.

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.

Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL; C-EDGE CO-STAR Study Group.

Ann Intern Med. 2016 Nov 1;165(9):625-634. doi: 10.7326/M16-0816. Epub 2016 Aug 9.

PMID:
27537841
29.

Nuclear receptors control pro-viral and antiviral metabolic responses to hepatitis C virus infection.

Levy G, Habib N, Guzzardi MA, Kitsberg D, Bomze D, Ezra E, Uygun BE, Uygun K, Trippler M, Schlaak JF, Shibolet O, Sklan EH, Cohen M, Timm J, Friedman N, Nahmias Y.

Nat Chem Biol. 2016 Dec;12(12):1037-1045. doi: 10.1038/nchembio.2193. Epub 2016 Oct 10.

PMID:
27723751
30.

Clinical management of acute liver failure: Results of an international multi-center survey.

Rabinowich L, Wendon J, Bernal W, Shibolet O.

World J Gastroenterol. 2016 Sep 7;22(33):7595-603. doi: 10.3748/wjg.v22.i33.7595.

31.

Non-alcoholic fatty liver and the gut microbiota.

Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E.

Mol Metab. 2016 Jun 14;5(9):782-94. doi: 10.1016/j.molmet.2016.06.003. eCollection 2016 Sep.

32.

Inadequate protein intake after laparoscopic sleeve gastrectomy surgery is associated with a greater fat free mass loss.

Sherf Dagan S, Tovim TB, Keidar A, Raziel A, Shibolet O, Zelber-Sagi S.

Surg Obes Relat Dis. 2017 Jan;13(1):101-109. doi: 10.1016/j.soard.2016.05.026. Epub 2016 Jun 2.

PMID:
27521254
33.

Non-alcoholic fatty liver disease is not associated with a lower health perception.

Mlynarsky L, Schlesinger D, Lotan R, Webb M, Halpern Z, Santo E, Shibolet O, Zelber-Sagi S.

World J Gastroenterol. 2016 May 7;22(17):4362-72. doi: 10.3748/wjg.v22.i17.4362.

34.

Response to The relationship between serum uric acid levels and NAFLD.

Zelber-Sagi S, Ben-Assuli O, Rabinowich L, Shalev V, Shibolet O, Chodick G.

Liver Int. 2016 May;36(5):769-70. doi: 10.1111/liv.13101. No abstract available.

PMID:
26923311
35.

Nutritional Status Prior to Laparoscopic Sleeve Gastrectomy Surgery.

Sherf Dagan S, Zelber-Sagi S, Webb M, Keidar A, Raziel A, Sakran N, Goitein D, Shibolet O.

Obes Surg. 2016 Sep;26(9):2119-2126. doi: 10.1007/s11695-016-2064-9. Erratum in: Obes Surg. 2017 Jun 12;:. Obes Surg. 2017 Jul 5;:.

PMID:
26797718
36.

Long-term culture and expansion of primary human hepatocytes.

Levy G, Bomze D, Heinz S, Ramachandran SD, Noerenberg A, Cohen M, Shibolet O, Sklan E, Braspenning J, Nahmias Y.

Nat Biotechnol. 2015 Dec;33(12):1264-1271. doi: 10.1038/nbt.3377. Epub 2015 Oct 26.

PMID:
26501953
37.

Assessment of Liver and Spleen Stiffness in Patients With Myelofibrosis Using FibroScan and Shear Wave Elastography.

Webb M, Shibolet O, Halpern Z, Nagar M, Amariglio N, Levit S, Steinberg DM, Santo E, Salomon O.

Ultrasound Q. 2015 Sep;31(3):166-9. doi: 10.1097/RUQ.0000000000000139.

PMID:
26366688
38.

Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease.

Rabinowich L, Shibolet O.

Biomed Res Int. 2015;2015:168905. doi: 10.1155/2015/168905. Epub 2015 Jul 26. Review.

39.

Treatment of hepatocellular carcinoma: Steps forward but still a long way to go.

Mlynarsky L, Menachem Y, Shibolet O.

World J Hepatol. 2015 Mar 27;7(3):566-74. doi: 10.4254/wjh.v7.i3.566. Review.

40.

The association between the serum levels of uric acid and alanine aminotransferase in a population-based cohort.

Zelber-Sagi S, Ben-Assuli O, Rabinowich L, Goldstein A, Magid A, Shalev V, Shibolet O, Chodick G.

Liver Int. 2015 Nov;35(11):2408-15. doi: 10.1111/liv.12842. Epub 2015 Apr 23.

PMID:
25845417
41.
42.

Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2.

Gane E, Kershenobich D, Seguin-Devaux C, Kristian P, Aho I, Dalgard O, Shestakova I, Nymadawa P, Blach S, Acharya S, Anand AC, Andersson MI, Arendt V, Arkkila P, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin C, Bessone F, Blokhina N, Brunton CR, Choudhuri G, Chulanov V, Cisneros L, Croes EA, Dahgwahdorj YA, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Gadano AC, Gower E, Halota W, Hatzakis A, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kostrzewska K, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Mossong J, Norris S, Nurmukhametova E, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prins M, Puri P, Radke S, Rakhmanova A, Razavi H, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V, Schréter I, Shah SR, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR, Prabdial-Sing N, Flisiak R, Estes C.

J Viral Hepat. 2015 Jan;22 Suppl 1:46-73. doi: 10.1111/jvh.12352.

PMID:
25560841
43.

The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.

Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, Schréter I, Baatarkhuu O, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Arkkila P, Barclay K, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Estes C, Flisiak R, Gane E, Gower E, Halota W, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Norris S, Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prabdial-Sing N, Prins M, Radke S, Rakhmanova A, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V, Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR, Puri P, Razavi H.

J Viral Hepat. 2015 Jan;22 Suppl 1:26-45. doi: 10.1111/jvh.12351.

PMID:
25560840
44.

Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2.

Saraswat V, Norris S, de Knegt RJ, Sanchez Avila JF, Sonderup M, Zuckerman E, Arkkila P, Stedman C, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin C, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Chulanov V, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Vree M, Estes C, Flisiak R, Gadano AC, Gane E, Halota W, Hatzakis A, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Mossong J, Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prabdial-Sing N, Prins M, Puri P, Radke S, Rakhmanova A, Razavi H, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanduijav R, Schréter I, Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Sokolov S, Souliotis K, Spearman CW, Staub T, Strebkova EA, Struck D, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuure FR, Silva MO, Sypsa V, Gower E.

J Viral Hepat. 2015 Jan;22 Suppl 1:6-25. doi: 10.1111/jvh.12350.

PMID:
25560839
45.

Prognosis of primary sclerosing cholangitis in israel is independent of coexisting inflammatory bowel Disease.

Yanai H, Matalon S, Rosenblatt A, Awadie H, Berdichevski T, Snir Y, Kopylov U, Katz L, Stein A, Mlynarsky L, Tulchinsky H, Konikoff FM, Horin SB, Braun M, Ben-Ari Z, Chowers Y, Baruch Y, Shibolet O, Dotan I.

J Crohns Colitis. 2015 Feb;9(2):177-84.

PMID:
25518055
46.

Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

Zelber-Sagi S, Salomone F, Webb M, Lotan R, Yeshua H, Halpern Z, Santo E, Oren R, Shibolet O.

Transl Res. 2015 Mar;165(3):428-36. doi: 10.1016/j.trsl.2014.10.008. Epub 2014 Oct 17.

PMID:
25468486
47.

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.

Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B.

Lancet. 2015 Mar 21;385(9973):1087-97. doi: 10.1016/S0140-6736(14)61793-1. Epub 2014 Nov 11.

PMID:
25467560
48.

Infiltrating monocyte-derived macrophages and resident kupffer cells display different ontogeny and functions in acute liver injury.

Zigmond E, Samia-Grinberg S, Pasmanik-Chor M, Brazowski E, Shibolet O, Halpern Z, Varol C.

J Immunol. 2014 Jul 1;193(1):344-53. doi: 10.4049/jimmunol.1400574. Epub 2014 Jun 2.

49.

Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial.

Zelber-Sagi S, Buch A, Yeshua H, Vaisman N, Webb M, Harari G, Kis O, Fliss-Isakov N, Izkhakov E, Halpern Z, Santo E, Oren R, Shibolet O.

World J Gastroenterol. 2014 Apr 21;20(15):4382-92. doi: 10.3748/wjg.v20.i15.4382.

50.

The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.

Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, Marcellin P, Caro L, Howe AY, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N.

Gastroenterology. 2014 Aug;147(2):366-76.e6. doi: 10.1053/j.gastro.2014.04.006. Epub 2014 Apr 12.

PMID:
24727022

Supplemental Content

Loading ...
Support Center